Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sotera Health ( (SHC) ) has shared an announcement.
On September 17, 2025, Sotera Health Company and its subsidiaries entered into an amendment to their First Lien Credit Agreement, originally dated December 13, 2019. This amendment involves refinancing term loans totaling approximately $1.42 billion, following a $75 million repayment using available cash, and includes a reduction in the interest rate spread by 0.50%. The repriced term loans, which mature on May 30, 2031, are subject to a 1.00% soft call premium for certain repricing transactions within six months of the amendment’s effective date, potentially impacting the company’s financial operations and cost of capital.
The most recent analyst rating on (SHC) stock is a Hold with a $16.50 price target. To see the full list of analyst forecasts on Sotera Health stock, see the SHC Stock Forecast page.
Spark’s Take on SHC Stock
According to Spark, TipRanks’ AI Analyst, SHC is a Neutral.
Sotera Health’s overall stock score is driven by a positive earnings call and strong technical indicators, indicating potential growth. However, high valuation and financial leverage pose risks. The company’s ability to manage debt and improve profitability will be crucial for future performance.
To see Spark’s full report on SHC stock, click here.
More about Sotera Health
Sotera Health is a company operating in the health sector, focusing on providing sterilization services, lab testing, and advisory services to ensure the safety of healthcare products.
Average Trading Volume: 1,716,452
Technical Sentiment Signal: Buy
Current Market Cap: $4.62B
Find detailed analytics on SHC stock on TipRanks’ Stock Analysis page.